Cargando…

Clinical trials in multiple sclerosis: potential future trial designs

Clinical trials of new treatments in multiple sclerosis (MS) currently require large sample sizes and long durations in order to yield reliable results. The differential responses of an already heterogeneous population of MS patients to individual disease-modifying therapies (DMTs) will further comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manouchehri, Navid, Zhang, Yinan, Salter, Amber, Hussain, Rehana Z., Hartung, Hans-Peter, Hemmer, Bernhard, Linker, Ralf, Segal, Benjamin M., Cutter, Gary, Stüve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535717/ https://www.ncbi.nlm.nih.gov/pubmed/31205492 http://dx.doi.org/10.1177/1756286419847095

Ejemplares similares

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity
por: Manouchehri, Navid, et al.
Publicado: (2023)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021)

To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Tugemann, Bastian, et al.
Publicado: (2022)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

Biological Significance of Anti–SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy
por: Manouchehri, Navid, et al.
Publicado: (2020)

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE
por: Hussain, Rehana Z., et al.
Publicado: (2018)

The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch
por: Stüve, Olaf, et al.
Publicado: (2014)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Editorial: Animal models of multiple sclerosis: can they advance future therapies?
por: DeSilva, Tara Maria, et al.
Publicado: (2023)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
por: Cravens, Petra D, et al.
Publicado: (2013)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis
por: Kuhbandner, Kristina, et al.
Publicado: (2019)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Improving the efficiency of clinical trials in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Glial cell transcriptome analyses in 3xTg-AD mice: Effects of aging, disease progression, and anti-Aβ immunotherapy
por: Lambracht-Washington, Doris, et al.
Publicado: (2023)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
por: Marrie, Ruth Ann, et al.
Publicado: (2014)

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation
por: Cravens, Petra D., et al.
Publicado: (2016)

Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey
por: Rinker, John R, et al.
Publicado: (2015)

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

CDP-choline to promote remyelination in multiple sclerosis: the need for a clinical trial
por: Gudi, Viktoria, et al.
Publicado: (2023)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a3e2mjvd2g3oqhr15tv33nridv